IntegraGen SA (ALINT.PA)
EUR 0.53
(0.0%)
EUR 0.53
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.12 Million EUR | -32.73% |
| 2022 | 1.67 Million EUR | -14.37% |
| 2021 | 1.95 Million EUR | -3.11% |
| 2020 | 2.01 Million EUR | 735.74% |
| 2019 | 241.15 Thousand EUR | -19.61% |
| 2018 | 300 Thousand EUR | 173310.4% |
| 2017 | 173.00 EUR | 6.13% |
| 2016 | 163.00 EUR | 3.82% |
| 2015 | 157.00 EUR | -38.19% |
| 2014 | 254.00 EUR | 167.37% |
| 2013 | 95.00 EUR | -48.65% |
| 2012 | 185.00 EUR | -99.99% |
| 2011 | 1.54 Million EUR | 3545.97% |
| 2010 | 42.37 Thousand EUR | -52.99% |
| 2009 | 90.13 Thousand EUR | 39087.39% |
| 2008 | 230.00 EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 869 Thousand EUR | 0.0% |
| 2023 Q2 | 1.37 Million EUR | 0.0% |
| 2023 FY | 1.12 Million EUR | -32.73% |
| 2023 Q4 | 1.12 Million EUR | 0.0% |
| 2022 Q4 | 1.67 Million EUR | 0.0% |
| 2022 Q2 | 1.88 Million EUR | 0.0% |
| 2022 FY | 1.67 Million EUR | -14.37% |
| 2021 Q4 | 1.95 Million EUR | 0.0% |
| 2021 FY | 1.95 Million EUR | -3.11% |
| 2021 Q2 | 1.98 Million EUR | 0.0% |
| 2020 FY | 2.01 Million EUR | 735.74% |
| 2020 Q2 | 2.02 Million EUR | 0.0% |
| 2020 Q4 | 2.01 Million EUR | 0.0% |
| 2019 Q4 | 241.15 Thousand EUR | 0.0% |
| 2019 Q2 | 270.65 Thousand EUR | 0.0% |
| 2019 FY | 241.15 Thousand EUR | -19.61% |
| 2018 Q2 | 434.94 Thousand EUR | 0.0% |
| 2018 FY | 300 Thousand EUR | 173310.4% |
| 2018 Q4 | 300 Thousand EUR | 0.0% |
| 2017 Q2 | 211.00 EUR | 0.0% |
| 2017 FY | 173.00 EUR | 6.13% |
| 2017 Q4 | 173.00 EUR | 0.0% |
| 2016 Q2 | 154.00 EUR | 0.0% |
| 2016 Q4 | 163.00 EUR | 0.0% |
| 2016 FY | 163.00 EUR | 3.82% |
| 2015 Q2 | 281.00 EUR | 0.0% |
| 2015 FY | 157.00 EUR | -38.19% |
| 2015 Q4 | 157.00 EUR | 0.0% |
| 2014 Q4 | 254.00 EUR | 0.0% |
| 2014 FY | 254.00 EUR | 167.37% |
| 2014 Q2 | 611.00 EUR | 0.0% |
| 2013 Q4 | 95.00 EUR | 0.0% |
| 2013 FY | 95.00 EUR | -48.65% |
| 2013 Q2 | 109.00 EUR | 0.0% |
| 2012 Q4 | 185.00 EUR | 0.0% |
| 2012 Q2 | 1.54 Million EUR | 0.0% |
| 2012 FY | 185.00 EUR | -99.99% |
| 2011 FY | 1.54 Million EUR | 3545.97% |
| 2011 Q2 | 228.00 EUR | 0.0% |
| 2011 Q4 | 1.54 Million EUR | 0.0% |
| 2010 Q4 | 42.37 Thousand EUR | 0.0% |
| 2010 FY | 42.37 Thousand EUR | -52.99% |
| 2010 Q2 | 748.44 Thousand EUR | 0.0% |
| 2009 FY | 90.13 Thousand EUR | 39087.39% |
| 2008 FY | 230.00 EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | 66.822% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 97.972% |
| Adocia SA | 13.08 Million EUR | 91.406% |
| Aelis Farma SA | 4.03 Million EUR | 72.146% |
| Biophytis S.A. | 8.27 Million EUR | 86.4% |
| Advicenne S.A. | 17.42 Million EUR | 93.545% |
| genOway Société anonyme | 7.23 Million EUR | 84.451% |
| Medesis Pharma S.A. | 1.2 Million EUR | 6.272% |
| Neovacs S.A. | 650 Thousand EUR | -73.036% |
| NFL Biosciences SA | 62.17 Thousand EUR | -1709.012% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 74.183% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | 58.601% |
| Sensorion SA | 2.86 Million EUR | 60.794% |
| Theranexus Société Anonyme | 3.64 Million EUR | 69.126% |
| TME Pharma N.V. | 1.16 Million EUR | 3.539% |
| Valbiotis SA | 6.87 Million EUR | 83.647% |
| TheraVet SA | 1.15 Million EUR | 3.029% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 87.5% |
| argenx SE | 18.1 Million EUR | 93.788% |
| BioSenic S.A. | 28.16 Million EUR | 96.006% |
| Celyad Oncology SA | 902 Thousand EUR | -24.693% |
| DBV Technologies S.A. | 13.01 Million USD | 91.361% |
| Galapagos NV | 9.59 Million EUR | 88.279% |
| Genfit S.A. | 70.17 Million EUR | 98.397% |
| GeNeuro SA | 7.73 Million EUR | 85.464% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | 78.755% |
| Innate Pharma S.A. | 39.89 Million EUR | 97.181% |
| Inventiva S.A. | 37.4 Million EUR | 96.993% |
| MaaT Pharma SA | 14.07 Million EUR | 92.009% |
| MedinCell S.A. | 58.96 Million EUR | 98.092% |
| Nanobiotix S.A. | 50.56 Million EUR | 97.776% |
| Onward Medical N.V. | 16.87 Million EUR | 93.335% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 91.783% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 97.544% |
| Oxurion NV | 12.33 Million EUR | 90.881% |
| Pharming Group N.V. | 155.29 Million EUR | 99.276% |
| Poxel S.A. | 46.9 Million EUR | 97.602% |
| GenSight Biologics S.A. | 18.42 Million EUR | 93.897% |
| Transgene SA | 1.25 Million EUR | 10.522% |
| Financière de Tubize SA | 79.2 Million EUR | 98.58% |
| UCB SA | 3.03 Billion EUR | 99.963% |
| Valneva SE | 208.81 Million EUR | 99.461% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -2859.829% |